Vor leads a new pack of IPOs to price, continuing steady stream of companies making leap to the Nasdaq
Vor Biopharma, Siddhartha Mukherjee’s cell therapy startup, officially priced its 9,828,017 shares of common stock Friday at $18 per share, raising $176.9 million. Vor’s IPO, trading under the ticker $VOR, will close Feb. 9, with Goldman Sachs, Evercore ISI, Barclays and Stifel operating as bookrunners.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.